SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Sofituzumab vedotin

Cat. No.: HY-P99593

CAS No.: 1418200-58-4

Target: Antibody-Drug Conjugates (ADCs)

Pathway: Antibody-drug Conjugate/ADC Related

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].

In Vitro

Sofituzumab vedotin (DMUC5754A) is an antibody–drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl[2].

Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000ng/mL; 3 or 5 days) inhibits OVCAR-3 and PC3/MUC16TMlong cells proliferation in a dose-dependent manner[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[3]

Cell Line:	OVCAR-3 and PC3/MUC16TMlong cells
Concentration:	0.1-10000 ng/mL
Incubation Time:	3 days for OVCAR-3 and 5 days for PC3/MUC16TMlong
Result:	Significantly inhibited cell proliferation above 100 ng/mL.

In Vivo

Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts [3]
Dosage:	2.8 mg/kg
Administration:	IV, once weekly for 4 total doses
Result:	Improved survival.

Animal Model:	Female CB17 ICR severe combined immunodeficient mice, OVCAR-3 tumors grown in the mammary fat pads[3]
Dosage:	2 mg/kg
Administration:	IV, once weekly for 3 total doses
Result:	Significantly decreased the tumor volume.

REFERENCES

[1]. Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223.

[2]. Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130.

[3]. Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA